ADVERTISEMENT
4 /5 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Regenxbio gets $40 million for licensing AAV9 to Abeona Therapeutics

by Ryan Cross
November 9, 2018 | APPEARED IN VOLUME 96, ISSUE 45

 

Abeona Therapeutics, a developer of gene therapies for lysosomal storage diseases, is paying Regenxbio at least $40 million for access to its adeno-associated virus 9 (AAV9) technology, used to deliver gene therapies into cells. Regenxbio could earn up to $140 million more. Abeona will use the technology in experimental therapies for Sanfilippo syndrome and Batten disease. Another user of Regenxbio’s AAV9 is Novartis, which expects the U.S. Food & Drug Administration to approve its spinal muscular atrophy therapy packaged in AAV9 next year.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment